Kornimate/medical-research-clean huggingface dataset:
arginine treatment of acute chest syndrome (pneumonia) in sickle cell disease patients

Conditions: Anemia, Sickle Cell; Pneumonia

Summary: this is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (scd) patients with acute chest syndrome (acs). it will also assess the effects of arginine in the body and how the body uses nitric oxide in acs.

pneumonia in patients with scd can be particularly severe and has come to be called acute chest syndrome. acs is a common cause of morbidity in scd patients and is the most common cause of death in scd. multiple factors are involved in the severity of acute pulmonary injury in scd. nitric oxide has a multitude of related functions, many of which could impact favorably on acs in scd. nitric oxide is an important inflammatory mediator which is produced by the conversion of l-arginine to citrulline by nitric oxide synthase. nitric oxide and its precursor, arginine, are known to be low in scd patients with acs, suggesting that therapies, such as arginine, aimed at increasing nitric oxide production will improve the clinical course of acs. patients will receive 1 of 3 doses of arginine hydrochloride orally 3 times a day for 3 days while hospitalized. the efficacy of arginine will be measured by the increase in nitric oxide production and the physiological effects will be assessed. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
inclusion criteria: * diagnosis of sickle cell disease (hb ss, sc, or sbeta thalassemia) acute chest syndrome with the following: * new pulmonary infiltrate on chest radiography involving a full segment of the lung and 1 of the following: * fever * cough, tachypnea, retractions, rales, or wheezing * chest pain exclusion criteria: * inability to take or tolerate oral medications * hepatic dysfunction (sgpt greater than 2 times normal) * renal dysfunction (creatinine greater than 2 times normal) * mental status or neurological changes * allergy to arginine * history of priapism * pregnancy

Keywords: nitric oxide administration, oral
clinical performance study of microbio infectid-bsi for detection of bacteria and yeast with patient blood samples

Conditions: Bloodstream Infection; Sepsis; Septic Shock

Summary: the objective of the study is to determine the efficacy of the microbio infectid-bsi qpcr kit in a clinical laboratory environment using patient whole blood for pathogen detection and identification versus standard of care methods from blood culture. the objective of this study is to determine the sensitivity and specificity of the microbio infectid-bsi qpcr kit by the evaluation of clinical blood samples versus standard of care methods from blood culture.


Eligibility criteria:
inclusion criteria: * male or female of neonates (less than 1 month of age), paediatrics (between 1 month and 17 years of age) or adults (\>18 years of age). * admitted to icu, emergency department, or other medical wards for acute illness with medical decision to perform blood culture for suspicion of bloodstream infection. * single edta blood sample collected from one anatomical site. * edta blood sample is stored according to microbio's stability requirements. * edta blood volume is \>1ml. exclusion criteria: * no suspicion of blood system infection. * any inclusion criterion not met. * multiple edta blood samples from the same patient. * edta blood samples that have not been stored according to microbio's stability requirements. * edta blood volume \<1ml.
a pilot test for newly developed synoptic operative template for ovarian cancer (sotoc): national cancer center - peritoneal carcinomatosis index

Conditions: Ovarian Cancer

Summary: objectives: to development of ncc-pci-operative template (npot) for the objective description of perioperative tumor burden and surgical approaches in the management of ovarian cancer, tubal cancer, and primary peritoneal cancer

* informed consent * digital photography \& checking pci (tumor size\& location ) * postoperative surveillance(tumor marker, image and physical examination) * developing the best fitting ncc-pci template to reflect recurrence and survival pattern

Eligibility criteria:
inclusion criteria: * preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary peritoneal carcinoma * available preoperative image study (ct and/or mri and/or pet) * patients who gave a written informed consent * patients must be surgical candidate considering medical and psychological condition exclusion criteria: * patients who refuse to participate or want to withdraw at anytime.

Keywords: pci,sotoc, ovarian cancer
an east asian study of lde225

Conditions: Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma

Summary: the purpose of this study is to determine maximum tolerated dose (mtd) or recommended phase ii dose of lde225 when administered orally to two adult patient groups of east asian (i.e., japanese and chinese/taiwanese) with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of advanced solid tumor (including medulloblastoma and basal cell carcinoma) * blood work criteria exclusion criteria: * patients with history of brain tumor (except recurrent medulloblastoma) or brain metastases * positive hiv, hepatitis b or c * impaired intestinal function * impaired heart function * pregnant or breast-feeding women other protocol-defined inclusion/exclusion criteria may apply

Keywords: advanced tumors hedgehog smoothened inhibitor
pain in competitive athletes with physical disabilities and techniques for its management

Conditions: Athletic Injuries; Physical Disability; Chronic Pain

Summary: there are psychosocial factors that affect pain, and therefore, psychological intervention techniques have been added to its usual pharmacological and physiotherapeutic treatment. despite the abundant evidence that addresses psychosocial factors as clear mediators in the perception of pain, the use of psychological techniques for pain management in competitive athletes, and more especially in competitive athletes with physical disabilities, is scarce. the purpose of this study was to ascertain the perception of high-level competitive athletes with physical disability and sports agents (coaches, physiotherapists and psychologists).

qualitative study with in-depth interviews to find out the perception of sports agents (coaches, physiotherapists and psychologists) and athletes on how pain can affect the development of the sports career and to determine what techniques are known and/or implemented by sports agents (coaches, physiotherapists and psychologists) and athletes to manage pain.

Eligibility criteria:
inclusion criteria: for the athlete: * physical disability. * participate in high performance competition * aged between 15 and 55 years old; for the sports agents: * to exercise their profession with high performance athletes with physical disabilities exclusion criteria: * not meeting the above requirements

Keywords: athlete physical disability competition chronic pain psychological models
ct coronary angiography and computational fluid dynamics

Conditions: Coronary Artery Disease

Summary: angiographically obtained fractional flow reserve(ffr) could provide functional and clinical information about stenotic lesion, but the invasiveness and measuring difficulty of ffr make it unfamiliar to perform. ct coronary angiography is non-invasive tool to evaluate lesion severity and lately developing computational fluid dynamics could provide functional information. the investigators build a patient specific model of computational fluid dynamics by ct coronary angiography and evaluate the functional significance by measuring fractional flow reserve via ct coronary angiography and computational fluid dynamics, and investigate its long-term prognostic implications.


Eligibility criteria:
inclusion criteria: * significant stenosis at ct angiography * normal ejection fraction on echocardiography * informed consented patient exclusion criteria: * total occlusion and collateral flow to target vessel * av conduction abnormality * left ventricular hypertrophy * significant valvular heart or primary myocardial disease

Keywords: coronary artery disease ct computational flow dynamics
palifermin for the reduction of oral mucositis in single-dose evaluation (promise)

Conditions: Cancer; Lymphoma; Leukemia

Summary: to evaluate whether palifermin (rhukgf) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (world health organization \[who\] grade 3 and 4).


Eligibility criteria:
inclusion criteria: * written informed consent * subjects with: non-hodgkin's lymphoma, hodgkin's disease, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, or multiple myeloma * minimum of 1.5 x 10\^6 cd34+ cells/kg cryopreserved and to be transplanted. exclusion criteria: * cancer other than those specified in inclusion criteria above (except: adequately treated basal cell carcinoma of the skin) * prior bone marrow or peripheral blood stem cell transplantation - negatively selected (purged) stem cell product - current active infection or oral mucositis * congestive heart failure as defined by new york heart association class iii or iv. * history of or current diagnosis of pancreatitis * inadequate renal function (serum creatinine greater than 1.5x the upper limit of normal per the institutional guidelines) * inadequate liver function (direct bilirubin greater than 1.5x the upper limit of normal, aspartate aminotransferase (ast) greater than 3x upper limit of normal and/or alanine aminotransferase (alt) greater than 3x upper limit of normal per the institutional guidelines) * inadequate pulmonary function as measured by a corrected diffusion capacity of carbon monoxide (dlco) less than 50% of predicted. * subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)

Keywords: cancer oncology
cardiac rehab post-atrial fib ablation

Conditions: Atrial Fibrillation

Summary: the aim of this study is to examine the effect of a 12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (af) in patients at six- and twelve-months post-ablation procedure.


Eligibility criteria:
inclusion criteria: * ● adult patients 18 years and older. * willing to participate in the study after randomization to either an intervention group (cardiac rehabilitation exercise) or a control group (usual care). * able to attend two pre and post study clinic visits at a local designated pulse heart institute cardiac rehab program. * if randomized to the cardiac rehab intervention group can attend exercise rehab visits for 3 x per week for 12 weeks (36 visits) at a designated pulse cardiac rehab program. * has an active email address and phone number. * documented diagnosis of paroxysmal and persistent atrial fibrillation. * undergone ablation treatment and is at a minimum of 2 weeks post ablation status. * compliant with medication therapy including medications for heart rate control and anticoagulant(s). exclusion criteria: * ● does not speak english. * does not have clearance to participate in the study by their attending cardiologist. * documented cardiovascular disease or pulmonary/respiratory disease that would qualify the patient for cardiac, pulmonary or vascular rehabilitation at a pulse heart institute rehabilitation program. * dementia or cognitive impairment. * unable to participate in rehabilitation exercise due to physical limitations. * greater than one prior ablation procedure * long standing, chronic atrial fibrillation * patients who have undergone posterior wall isolation ablation.
assessment of asthma control level in malaysia

Conditions: Asthma Control Level

Summary: a non-interventional retrospective study to assess the level of asthma control among adults at 2 tertiary care centres in malaysia; institute of respiratory medicine (ipr) and hospital serdang. the specific objective of the study is to assess, in real-life clinical practice in malaysia, the level of gina-defined asthma control and the potential risk factors for uncontrolled disease in asthma patients

despite the availability of gina global guideline on asthma management which is widely referred by health care providers in malaysia, the control of asthma is still a critical challenge. according to national health and morbidity survey 2011, the prevalence of asthma in malaysia is at 6.3%. based on self-rated health status, 5.5% of patients were reported to be in good health whereas 9.9% reported poor health status although medications such as inhaled corticosteroids (ics) and long-acting beta agonists (laba) are widely available for effective asthma management. there is limited data to assess the level of asthma control in malaysia which includes current clinical manifestation and future risk of exacerbation. given the lack of data on asthma control level, the awareness on the current disease control level will assist to properly characterise the patients based on gina control level thus leading to appropriate diagnosis and treatment. the specific objective of the study is to assess, in real-life clinical practice in malaysia, the level of gina-defined asthma control and the potential risk factors for uncontrolled disease in asthma patients

Eligibility criteria:
inclusion criteria: * all patients with gina-defined clinical diagnosis of asthma seen at respiratory clinic from january to august 2016. * be at least 18 years of age exclusion criteria: * clinical features suggesting emphysema or chronic bronchitis * other de-compensated organ failures
penicillin allergy testing and resensitization rate

Conditions: Penicillin Allergy

Summary: penicillin is one of the earliest discovered antibiotics and a drug of choice for several infections. up to 10 to 20% of all patients in clinical trial are labeled as penicillin allergic. most of these patients do not have a true allergy but few have had it verified. approximately 80% of patients with ige-mediated penicillin allergy lose their sensitivity after 10 years. several studies have been conducted denying the risk of sensitization following negative testing of penicillin allergy. investigators have not had the same experience and have therefore decided to conduct a retrospective study review of 83 adult outpatients with a distant penicillin allergy label and evaluate outcomes of skin retesting six weeks following drug provocation test and challenge.


Eligibility criteria:
inclusion criteria: - 18 years old exclusion criteria: * pregnancy * poorly controlled asthma and cardiovascular disease * use of drugs that interfere with testing and could not be stopped such as antihistamines, tricyclic antidepressants, antipsychotics, beta blockers, high dose oral glucocorticoids * non-ige mediated type of serious allergic reaction such as stevens - johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (dress) syndrome.
mis-c comparative effectiveness study

Conditions: Multisystem Inflammatory Syndrome-Children

Summary: in march 2020, children exposed to the virus that causes the covid-19 illness, sars-cov-2, presented with fever and significant inflammation about a month after exposure to the virus. some children were sick enough to require care in the intensive care unit for what came to be known as multisystem inflammatory syndrome-children (mis-c).the clinical presentation shared many features with kawasaki disease (kd), a self-limited inflammation that can cause ballooning of the arteries of the heart. thus, physicians reached for many of the therapies used to treat children with kd. despite the surge of covid-19 cases and children continuing to present with mis-c, there are no data that guide the choice of therapy. thus, the investigators have designed a study to determine which combination of therapies is most effective in helping children with mis-c recover quickly.

this study is a multi-site, randomized, pragmatic, comparative effectiveness study of children with mis-c. the current standard of care is that all mis-c patients are initially treated with ivig and receive additional therapy if they are severely ill or do not improve clinically. this study design will randomize subjects who have received ivig but clinically warrant further anti-inflammatory therapy to one of three treatment arms (infliximab, steroids or anakinra) and allow for re-randomization to one of the two remaining arms if clinically warranted.

Eligibility criteria:
inclusion criteria: 1. an individual aged \<21 years presenting with 1. fever (\>38.0°c for ≥24 hours; may be by subjective report) and 2. two or more of the following (from two different systems; e.g. one from cardiac and one from mucocutaneous): cardiac * hypotension * shock * arrhythmia * tachycardia * left ventricular ejection fraction \<55% * valvulitis * coronary artery enlargement (lad or rca z-score ≥ 2.5) * pericardial effusion gastrointestinal * diarrhea * nausea/vomiting * significant abdominal pain immunologic * lymphadenopathy (unilateral cervical or diffuse) mucocutaneous * bilateral conjunctival injection * extremity swelling or erythema * rash * lip erythema/strawberry tongue neurologic * altered mental status * focal neurological deficits * headache * meningismus 3. laboratory evidence of inflammation, including but not limited to, an elevated c-reactive protein (crp), erythrocyte sedimentation rate (esr), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (ldh), neutrophilia, lymphopenia or hypoalbuminemia and 4. no alternative plausible diagnoses based on clinical judgement and 5. positive for current or recent sars-cov-2 infection by rt-pcr, serology, or antigen test; or suspected covid-19 exposure and 6. parent or legal guardian (or self if at least 18 years old) able and willing to provide informed consent and subject willing and able to provide assent when appropriate. exclusion criteria: 1. known immunodeficiency 2. pre-existing medical condition that precludes receiving one or more of the study medications (e.g. tb, drug allergy to study medication).
furmonertinib as perioperation therapy in stage iiia-iiib (n1-n2) resectable egfr mutated lung adenocarcinoma (front)

Conditions: Lung Adenocarcinoma

Summary: this is a phase ii study aimed to assess the efficacy and safety of furmonertinib, a third generation egfr tki, as perioperation therapy in stage iiia-iiib (n1-n2) resectable nsclc patients.

please refer to detailed description in the following context.

Eligibility criteria:
inclusion criteria: * the written informed consent of the patients has been obtained before any examination, sampling and analysis related to the study. * primary lung adenocarcinoma diagnosed histologically/cytologically. * stages iiia-iiib (n1-n2) according to the ajcc 8th edition lung cancer stage and plan to receive radical excision judged by investigators. * egfr mutation positive (19del or l858r, with or without t790m) * the presence of at least one measurable lesion and suitable for accurate repeated measurements. * ecog performance status 0-1. * for premenopausal women with fertility, the result of serum or urine pregnancy test should be negative within 7 days before the first dose. exclusion criteria: * squamous cell carcinoma, and tumors with neuroendocrine components such as large cell carcinoma, or small cell carcinoma. * patients with egfr exon 20 insertion mutation. * exposure to other antitumor therapies prior to enrolment. * major surgery was performed in the four weeks prior to the first dosing of the study drug. * pregnant or lactating female patients. * use of cyp3a4 strong depressant within 7 days or cyp3a4 strong inducer within 21 days prior to initial administration. * have a history of or present complications with other malignancies. * patients with severe or uncontrolled systemic disease requiring treatment were not considered suitable for the study. * ecg qt interval prolongation or associated risk. * a history of interstitial pneumonia or related risk. * inadequate bone marrow or organ reserve. * other circumstances that are not suitable for participation in this study.
predictive tracking of patient flow in the emergency services during the virus winter epidemics

Conditions: Disease Outbreaks; Child; Elderly; Bronchiolitis; Acute Renal Failure

Summary: epidemics and infectious diseases in general, punctuate much of the activity of an emergency service. the impact of winter infections is particularly important to vulnerable populations such as infant during bronchiolitis epidemics and the elderly during seasonal influenza. each year, these epidemic phenomena lead to disorganization of emergency services and healthcare teams by lack of anticipation and organizational measures in particular to manage the approval of emergency services for the most vulnerable populations requiring hospitalization. for 2 years, the pediatric emergency department of st etienne university hospital has a decision support tool for the periods of winter epidemics. through a retrospective analysis of passages of emergency summary, this tool provides an estimate of infants with bronchiolitis flow day to day, and the availability in real time of an abnormally high flow of patients to pediatric emergencies. these data can help to affirm that the epidemic begins in this hospital.


Eligibility criteria:
inclusion criteria: * child \< 24 months with bronchiolitis * elderly \< 60 years with acute renal failure or breathing problem exclusion criteria: * refuse of transmission of their data
safety study of autologous bone marrow stromal cells with modification by hepatocyte growth factor to treat silicosis

Conditions: Silicosis

Summary: the aim of this study was to analyze the safety, pulmonary function, and imaging changes of patients with silicosis treated with autologous bone marrow stromal cells with modification by hepatocyte growth factor.


Eligibility criteria:
inclusion criteria: - age between 18-50, chronic and accelerated silicosis, characterized with a fibrotic increase in the last two years, fev1 \ 40%, fvc \> 60% and sao2 \>90% exclusion criteria: - smoking, active tuberculosis or other infections, cancer, auto-immune disorders, hematological, hepatic or cardiac diseases, and pregnancy